All News

Taking a deeper dive: Novel gene therapy approaches to treat ocular disease

September 23, 2020

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats

Robotics allow surgeons to perform the seemingly impossible

September 22, 2020

Automated assistance controls tremor, reduces fatigue, and helps avoid inadvertent injury

Bausch Health to acquire option to purchase ophthalmology assets of Allegro

September 21, 2020

Agreement would include global rights for investigational treatment, risuteganib, expected to help reverse vision loss due to dry AMD

Big data: Driving opportunity for real-world evidence

September 21, 2020

Evidence-based medicine can lead to personalized care, better results for patients

Surgical pearls for staying sharp during the COVID-19 pandemic

September 18, 2020

Ophthalmologists remain in touch with colleagues while maintaining social distancing

Harnessing regeneration of retinal tissues: An option almost within reach

September 17, 2020

This ability would unlock possibilities for repairing tissue damaged by disease

Persistent retinal detachment associated with retinoblastoma

September 16, 2020

Watchful waiting may prove to be beneficial in complicated cases

Targeting AMD patient treatment burden

September 15, 2020

Intravitreal gene therapy continues to be well tolerated; shows robust efficacy

Novartis: Positive DME data for brolucizumab in KITE trial

September 14, 2020

Novartis has announced positive topline results from the phase 3 KITE study of brolucizumab 6 mg versus aflibercept for patients with diabetic macular edema.

OCTA: Why the jury may still be out

September 11, 2020

Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.